Turnstone Biologics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $9.6M

  • Investors
  • 1

Turnstone Biologics General Information

Description

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Contact Information

Formerly Known As
Turnstone Biologics Inc.
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 9310 Athena Circle
  • Suite 300
  • La Jolla, CA 92037
  • United States
Primary Industry
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 9310 Athena Circle
  • Suite 300
  • La Jolla, CA 92037
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Turnstone Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 11-Aug-2025 $9.6M Completed Generating Revenue
8. IPO 21-Jul-2023 Completed Generating Revenue
7. Later Stage VC (Series D) 14-Jul-2021 Completed Clinical Trials - Phase 1
6. Later Stage VC 19-Dec-2019 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series C) 04-Jan-2019 Completed Pre-Clinical Trials
4. Early Stage VC (Series B) 02-Nov-2016 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 28-Oct-2015 Completed Pre-Clinical Trials
2. Early Stage VC 04-May-2015 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2014 Completed Pre-Clinical Trials
To view Turnstone Biologics’s complete valuation and funding history, request access »

Turnstone Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure
Biotechnology
La Jolla, CA
3 As of 2025

Waltham, MA
 

Rochester, MN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Turnstone Biologics Competitors (60)

One of Turnstone Biologics’s 60 competitors is TScan Therapeutics, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TScan Therapeutics Formerly VC-backed Waltham, MA
Vyriad Venture Capital-Backed Rochester, MN
Instil Bio Formerly VC-backed Dallas, TX
Dendreon Formerly VC-backed Seal Beach, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 60 competitors. Get the full list »

Turnstone Biologics Patents

Turnstone Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025096638-A2 Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same Inactive 30-Oct-2023
WO-2025096638-A3 Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same Inactive 30-Oct-2023
WO-2025080865-A1 Combination of tumor infiltrating lymphocytes (til) and low dose radiation Inactive 11-Oct-2023
WO-2024192051-A1 Composition of selected tumor infiltrating lymphocytes and related methods of producing and using the same Inactive 13-Mar-2023
US-20260199414-A1 Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors Pending 16-Dec-2022 A61K35/76
To view Turnstone Biologics’s complete patent history, request access »

Turnstone Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Turnstone Biologics Former Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brace Pharma Capital Corporate Venture Capital Minority
CaaS Capital Management Hedge Fund Minority
Eight Roads Corporate Venture Capital Minority
Eventide Asset Management Venture Capital Minority
F-Prime Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Turnstone Biologics Acquisitions (1)

Turnstone Biologics’s most recent deal was a Merger/Acquisition with Myst Therapeutics. The deal was made on 20-Jan-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Myst Therapeutics 20-Jan-2021 Merger/Acquisition Biotechnology
To view Turnstone Biologics’s complete acquisitions history, request access »

Turnstone Biologics ESG

Risk Overview

Risk Rating

Updated October, 31, 2025

33.82 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view Turnstone Biologics’s complete esg history, request access »

Turnstone Biologics FAQs

  • When was Turnstone Biologics founded?

    Turnstone Biologics was founded in 2014.

  • Where is Turnstone Biologics headquartered?

    Turnstone Biologics is headquartered in La Jolla, CA.

  • What is the size of Turnstone Biologics?

    Turnstone Biologics has 3 total employees.

  • What industry is Turnstone Biologics in?

    Turnstone Biologics’s primary industry is Biotechnology.

  • Is Turnstone Biologics a private or public company?

    Turnstone Biologics is a Private company.

  • What is the current valuation of Turnstone Biologics?

    The current valuation of Turnstone Biologics is .

  • What is Turnstone Biologics’s current revenue?

    The current revenue for Turnstone Biologics is .

  • How much funding has Turnstone Biologics raised over time?

    Turnstone Biologics has raised $375M.

  • Who are Turnstone Biologics’s investors?

    Brace Pharma Capital, CaaS Capital Management, Eight Roads, Eventide Asset Management, and F-Prime are 5 of 19 investors who have invested in Turnstone Biologics.

  • Who are Turnstone Biologics’s competitors?

    TScan Therapeutics, Vyriad, Instil Bio, Dendreon, and Kite Pharma are some of the 60 competitors of Turnstone Biologics.

  • When was Turnstone Biologics acquired?

    Turnstone Biologics was acquired on 11-Aug-2025.

  • Who acquired Turnstone Biologics?

    Turnstone Biologics was acquired by Xoma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process